New Single-Tablet HIV Regimen Shows Promise for Virologic Suppression

A new once-daily single tablet regimen combining bictegravir and lenacapavir is demonstrating promising results in maintaining virologic suppression in adults living with HIV. The investigational combination, dubbed BIC/LEN, offers a potential new option for individuals currently on complex multi-tablet regimens or seeking alternatives to existing treatments like Biktarvy.

ARTISTRY Trials Demonstrate Non-Inferiority

Phase 3 clinical trials, known as ARTISTRY-1 and ARTISTRY-2, have shown that BIC/LEN is statistically non-inferior to Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets) in maintaining viral suppression. The primary efficacy endpoint in the ARTISTRY-2 trial was the percentage of participants with HIV-1 RNA levels ≥50 copies/mL at Week 48, assessed using the FDA snapshot algorithm. Gilead Sciences announced positive topline results from the ARTISTRY-2 trial on December 15, 2025.

How BIC/LEN Works

The investigational regimen combines bictegravir, an integrase strand transfer inhibitor recommended in global guidelines, with lenacapavir, a first-in-class capsid inhibitor. Lenacapavir has a unique mechanism of action with no overlapping resistance to other existing drug classes. The Lancet reports on the development of bictegravir–lenacapavir for treatment of HIV-1.

Potential Benefits and Future Outlook

The development of BIC/LEN could simplify treatment for people living with HIV, potentially improving adherence and quality of life. Gilead plans to submit the results from the ARTISTRY trials to regulatory authorities and present detailed findings at a future scientific congress. Fierce Pharma highlights Gilead’s efforts to create another single-tablet option to fill treatment gaps.

Regulatory Pathway and Competition

Alongside Gilead’s progress, Merck is also advancing a daily HIV pill, creating a competitive landscape in the development of simplified HIV treatment options. BioSpace reports on the race between Gilead and Merck to bring their respective daily HIV pills to market.